Last week (November 15-19), the market rose steadily, and the Shanghai index rose slightly by 0.6% to 3560.37 points, realizing two consecutive positive days on the weekly line. The heat of institutional research has also increased. As of press time, 187 Shanghai and Shenzhen companies have disclosed the records of investor relations activities during the week, an increase of more than 30% over the previous week.
By industry (Shenwan industry), mechanical equipment, chemical industry and electronics received more attention. Last week, 37, 23 and 14 companies in the industry received research respectively. In the secondary market, the mechanical equipment and chemical sectors rose 1.51% and 0.17% respectively throughout the week, while the electronic industry fell 0.40%.
In terms of individual stock heat, Kechuang board Biomedical Company Qingdao Haier Biomedical Co.Ltd(688139) (688139) was the most popular last week. From November 15 to 17, a total of 154 institutions investigated Qingdao Haier Biomedical Co.Ltd(688139) through on-site or teleconference, including many well-known institutions such as Shanghai Investment Morgan, SDIC UBS, Harvest Fund and e fund. The stock rose 3.59% to 88.09 yuan / share, with the latest market value of about 28 billion yuan.
In addition, Leyard Optoelectronic Co.Ltd(300296) and Zhejiang Yongtai Technology Co .Ltd(002326) also received research from more than 100 institutions last week. Among them, LED application leader Leyard Optoelectronic Co.Ltd(300296) rose 2.26% last week. Electrolyte upstream materials company Zhejiang Yongtai Technology Co .Ltd(002326) experienced a high correction, down about 20% in the week.
In terms of other stars receiving research shares, Byd Company Limited(002594) , Midea Group Co.Ltd(000333) , Aier Eye Hospital Group Co.Ltd(300015) , Bank Of Ningbo Co.Ltd(002142) , Chongqing Zhifei Biological Products Co.Ltd(300122) , Gf Securities Co.Ltd(000776) , Yunnan Baiyao Group Co.Ltd(000538) and Wens Foodstuff Group Co.Ltd(300498) many companies with a market value of 100 billion also received research within the week.
Review the research records of Qingdao Haier Biomedical Co.Ltd(688139) . The organization mainly focuses on the development of the company’s main business such as Internet of things solution business, overseas distribution network system construction and future planning. Qingdao Haier Biomedical Co.Ltd(688139) is a leader in the biomedical cryogenic storage equipment industry, and is now committed to the transformation to a biosafety solution provider.
Since this year, Qingdao Haier Biomedical Co.Ltd(688139) share prices have experienced ups and downs. Although the annual increase of the stock has increased by more than 30%, since the intraday record high of 150.88 yuan / share on August 19 this year, Qingdao Haier Biomedical Co.Ltd(688139) the share price has retreated by more than 40% in the past three months.
however, institutional investors have always paid high attention to Qingdao Haier Biomedical Co.Ltd(688139) . In particular, since the disclosure of the third quarterly report, Qingdao Haier Biomedical Co.Ltd(688139) has intensively received many batches of institutions in recent months. Since October 28, the company has disclosed four records of investor relations activities, with nearly 300 reception institutions.
According to the financial report, Qingdao Haier Biomedical Co.Ltd(688139) 2021 achieved an operating revenue of 1.52 billion yuan in the first three quarters, a year-on-year increase of 54.89%; The net profit attributable to the parent company was 698 million yuan, a year-on-year increase of 156.28%.
In the latest research activity, Qingdao Haier Biomedical Co.Ltd(688139) introduced that the scenario integrated solution represented by the Internet of things solution business has always been the key direction of the company’s business development. In the first three quarters of 2021, the business revenue of Internet of things solutions increased by 155.45%, accounting for 28.71% of the overall revenue. In addition, in the first three quarters, the company’s overseas distribution business revenue increased by 35.65% year-on-year, 184 new dealers were added, and localized sales teams were successively established in the United States, Vietnam and other countries.
For future planning, Qingdao Haier Biomedical Co.Ltd(688139) revealed that the current production capacity and orders are stable. At the same time, in order to reserve relevant production capacity in advance and support subsequent Shenzhen New Industries Biomedical Engineering Co.Ltd(300832) continuous incubation, a Qingdao Haier Biomedical Co.Ltd(688139) safety science and Innovation Industrial Park will be built in Qingdao high tech Zone, which is expected to be put into operation in 2023. In the future, the company will seize the development opportunities of the country to vigorously promote the biosafety industry and “new infrastructure”, and constantly expand new products and new scenes.
(E company)
